Sanofi: Alirocumab delivers on promises

BUY, Fair Value EUR94 (+14%)

News published on September Monday 1, 2014
Share on
Data disclosed at the ESC confirm efficacy of PCSK9 inhibitors on LDL-c over 52-78 weeks. A trend towards a cv mortality benefit is seen. Only neurognitive adverse events will have to be monitored.

For further information please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities